Compile Data Set for Download or QSAR
Report error Found 155 Enz. Inhib. hit(s) with all data for entry = 12628
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716172(US12209085, Example 215)
Affinity DataIC50: 0.0600nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716174(US12209085, Example 214)
Affinity DataIC50: 0.100nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716185(US12209085, Example 227)
Affinity DataIC50: 0.130nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716229(US12209085, Example 287)
Affinity DataIC50: 0.130nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716201(US12209085, Example 250)
Affinity DataIC50: 0.140nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716207(US12209085, Example 256)
Affinity DataIC50: 0.140nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716195(US12209085, Example 244)
Affinity DataIC50: 0.150nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716198(US12209085, Example 247)
Affinity DataIC50: 0.150nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716209(US12209085, Example 258)
Affinity DataIC50: 0.150nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716172(US12209085, Example 215)
Affinity DataIC50: 0.160nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

LigandPNGBDBM716172(US12209085, Example 215)
Affinity DataIC50: 0.160nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716210(US12209085, Example 259)
Affinity DataIC50: 0.160nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716178(US12209085, Example 186)
Affinity DataIC50: 0.170nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716208(4-(6-(6-(3-(3-fluoropyridin-2-yl)prop-2-yn-1-yl)pi...)
Affinity DataIC50: 0.170nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [M918T](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716172(US12209085, Example 215)
Affinity DataIC50: 0.183nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716171(US12209085, Example 4)
Affinity DataIC50: 0.200nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716212(US12209085, Example 262)
Affinity DataIC50: 0.200nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716229(US12209085, Example 287)
Affinity DataIC50: 0.200nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716209(US12209085, Example 258)
Affinity DataIC50: 0.210nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716236(US12209085, Example 220)
Affinity DataIC50: 0.220nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716173(US12209085, Example 194)
Affinity DataIC50: 0.230nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716203(US12209085, Example 252)
Affinity DataIC50: 0.25nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

LigandPNGBDBM716173(US12209085, Example 194)
Affinity DataIC50: 0.260nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716170(US12209085, Example 3)
Affinity DataIC50: 0.270nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716171(US12209085, Example 4)
Affinity DataIC50: 0.270nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716195(US12209085, Example 244)
Affinity DataIC50: 0.270nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716231(US12209085, Example 187)
Affinity DataIC50: 0.280nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716232(US12209085, Example 195)
Affinity DataIC50: 0.290nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716170(US12209085, Example 3)
Affinity DataIC50: 0.300nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716174(US12209085, Example 214)
Affinity DataIC50: 0.300nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [M918T](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716174(US12209085, Example 214)
Affinity DataIC50: 0.300nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716185(US12209085, Example 227)
Affinity DataIC50: 0.300nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716192(US12209085, Example 238)
Affinity DataIC50: 0.300nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716230(US12209085, Example 2)
Affinity DataIC50: 0.350nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716233(US12209085, Example 217)
Affinity DataIC50: 0.350nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716186(US12209085, Example 232)
Affinity DataIC50: 0.370nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716176(US12209085, Example 5)
Affinity DataIC50: 0.390nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716183(US12209085, Example 225)
Affinity DataIC50: 0.390nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716191(US12209085, Example 237)
Affinity DataIC50: 0.390nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716200(US12209085, Example 249)
Affinity DataIC50: 0.390nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716220(US12209085, Example 276)
Affinity DataIC50: 0.390nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716225(US12209085, Example 283)
Affinity DataIC50: 0.390nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716189(US12209085, Example 235)
Affinity DataIC50: 0.400nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716172(US12209085, Example 215)
Affinity DataIC50: 0.420nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716180(US12209085, Example 222)
Affinity DataIC50: 0.430nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716222(US12209085, Example 280)
Affinity DataIC50: 0.430nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716207(US12209085, Example 256)
Affinity DataIC50: 0.440nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716181(US12209085, Example 223)
Affinity DataIC50: 0.480nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716187(US12209085, Example 233)
Affinity DataIC50: 0.5nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Sunshine Lake Pharma Co.

US Patent
LigandPNGBDBM716234(US12209085, Example 218)
Affinity DataIC50: 0.520nMAssay Description:1. Experimental Purpose:The inhibitory activities of the series of compounds against Ret wt, VEGFR2, CCDC6-RET, Ret M918T, Ret V804L, and Ret V804M w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/3/2025
Entry Details
Go to US Patent

Displayed 1 to 50 (of 155 total ) | Next | Last >>
Jump to: